Wordt geladen...
Future agents and treatment directions in multiple myeloma
The development of bortezomib and IMIDs resulted in a revolution in the treatment of MM. Moreover, second-generation proteasome inhibitors (carfilzomib) and IMIDs (pomalidomide) have recently been approved. Nevertheless, the incurability of this disease requires other drugs with different mechanisms...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4157182/ https://ncbi.nlm.nih.gov/pubmed/24350987 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2014.858595 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|